Preclinical QT safety assessment: Cross-species comparisons and human translation from an industry consortium

导出原文传递

翻译打印收藏纠错

作者： Holzgrefe,H. ^[1] ; Ferber,G. ^[2] ; Champeroux,P. ^[3] ; Gill,M. ^[4] ; Honda,M. ^[5] ; Greiter-Wilke,A. ^[6] ; Baird,T. ^[7] ; Meyer,O. ^[8] ; Saulnier,M.

作者单位： Chugai Pharmaceutical Co. Ltd., Research Division, 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan ^[1] F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland ^[2] Bristol-Myers Squibb, Discovery Toxicology, Route 206 and Provinceline Road, Princeton, NJ 08543 ^[3] Statistik Georg Ferber GmbH, Cagliostrostrasse 14, 4125 Riehen, Switzerland ^[4] MPI Research Inc., 54943 North Main Street, Mattawan, MI 49071, United States ^[5] Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue ^[6] Charles River Laboratories, 6995 Longley Lane, Reno, NV 89511, United States ^[7] Centre de Recherches Biologiques, CERB, Chemin de Montifault, 18800 Baugy, France ^[8]

关键词 Biomarker Cynomolgus monkey Dog Guinea pig Marmoset Methods Minipig Moxifloxacin Preclinical-clinical concordance QT rate-correction

发布时间 2014-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交